Mersana Therapeutics Intrinsic Value Calculation – MERSANA THERAPEUTICS Reports 148.8% Increase in Revenue for FY2023 Q2

August 12, 2023

☀️Earnings Overview

MERSANA THERAPEUTICS ($NASDAQ:MRSN) reported total revenue of USD 10.7 million for Q2 of the 2023 fiscal year ending June 30, 2023, representing a 148.8% increase from the same quarter in the prior year. Net income for the quarter was reported to be USD -54.3 million, compared to -52.2 million in the same quarter of the previous year.

Analysis – Mersana Therapeutics Intrinsic Value Calculation

MERSANA THERAPEUTICS, a publicly traded biopharmaceutical company, can be analyzed with GoodWhale’s financial analysis tools. According to our proprietary Valuation Line, the intrinsic value of MERSANA THERAPEUTICS share is calculated to be around $1659.0. This value is substantially higher than the current market price of $1.2, suggesting that MERSANA THERAPEUTICS is undervalued by 99.9%. Therefore, it may be a good option to buy the stock now and reap the rewards when it reaches its intrinsic value. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis
  • About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Mersana Therapeutics. More…

    Total Revenues Net Income Net Margin
    38.72 -215.21 -555.8%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Mersana Therapeutics. More…

    Operations Investing Financing
    -87.47 -65.96 146.82
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Mersana Therapeutics. More…

    Total Assets Total Liabilities Book Value Per Share
    311 221.2 0.75
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Mersana Therapeutics are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    183.8% -545.9%
    FCF Margin ROE ROA
    -232.4% -171.4% -42.5%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items

  • Peers

    The company’s lead product candidate, XMT-1536, is in clinical development for the treatment of solid tumors. Mersana has two other ADC product candidates in development, XMT-1522 and XMT-1592. Mersana’s main competitors are Sensei Biotherapeutics Inc, IMV Inc, and Immunome Inc. These companies are also focused on developing cancer therapies, including ADCs.

    – Sensei Biotherapeutics Inc ($NASDAQ:SNSE)

    Sensei Biotherapeutics Inc is a clinical-stage immuno-oncology company. The company is focused on developing and commercializing its proprietary platform of off-the-shelf, anti-sense oligonucleotide therapeutics to treat a range of solid tumors and hematologic malignancies.

    – IMV Inc ($TSX:IMV)

    IMV Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of cancer immunotherapies and other immune modulating agents. Its product candidates include DPX-Survivac, T cell Receptor, and Antibody Programs. The company was founded by Frederic Ors on December 15, 1999 and is headquartered in Halifax, Canada.

    – Immunome Inc ($NASDAQ:IMNM)

    Immunome Inc is a clinical stage biopharmaceutical company that focuses on the development of monoclonal antibody therapeutics for the treatment of cancer. The company has a market cap of 56.88M as of 2022 and a return on equity of -65.38%. The company’s focus on the development of monoclonal antibody therapeutics for the treatment of cancer makes it a unique player in the biopharmaceutical industry. The company’s clinical stage status also makes it a high-risk investment, but one that could offer high rewards if the company’s products are successful in the marketplace.


    MERSANA THERAPEUTICS reported strong financial results for its second quarter of Fiscal Year 2023, with total revenues of USD 10.7 million, representing a 148.8% increase YoY. Net income was reported to be a loss of USD 54.3 million, which was a slight improvement compared to the same quarter in the prior year. Investors may be encouraged by the revenue growth, however losses remain a concern. The company should be monitored closely for future developments to determine if it is a suitable investment opportunity.

    Recent Posts

    Leave a Comment